Ying Tan

Dr. Ying Tan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SYSha Yang
Sha Yang
JGJing Guo
Jing Guo
ZKZhuo Kong
Zhuo Kong
MDMei Deng
Mei Deng
JDJingjing Da
Jingjing Da
JZJiqin Zhang
Jiqin Zhang
Background: Gut microbiota alterations have been implicated in sepsis and related infectious diseases, but the causal relationship and underlying mechanisms remain unclear. Methods: We evaluated the association between gut microbiota composition and sepsis using two-sample Mendelian randomization (MR) analysis based on published genome-wide association study (GWAS) summary statistics. Sensitivity analyses were conducted to validate the robustness of the results. Reverse MR analysis and integration of GWAS and expression quantitative trait loci (eQTL) data were performed to identify potential genes and therapeutic targets. Results: Our analysis identified 11 causal bacterial taxa associated with sepsis, with increased abundance of six taxa showing positive causal relationships. Ten taxa had causal effects on the 28-day survival outcome of septic patients, with increased abundance of six taxa showing positive associations. Sensitivity analyses confirmed the robustness of these associations. Reverse MR analysis did not provide evidence of reverse causality. Integration of GWAS and eQTL data revealed 76 genes passing the summary data-based Mendelian randomization (SMR) test. Differential expression of these genes was observed between sepsis patients and healthy individuals. These genes represent potential therapeutic targets for sepsis. Molecular docking analysis predicted potential drug-target interactions, further supporting their therapeutic potential. Conclusion: Our study provides insights for the development of personalized treatment strategies for sepsis and offers preliminary candidate targets and drugs for future drug development.

7 November 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
JGJing Guo
Jing Guo
DKDexun Kong
Dexun Kong
JLJunchi Luo
Junchi Luo
TXTao Xiong
Tao Xiong
FWFang Wang
Fang Wang
JZJiqin Zhang
Jiqin Zhang
Background: Oxidative stress‐induced inflammation is a major pathogenic mechanism in sepsis‐associated encephalopathy (SAE). We hypothesized that regulation of reactive oxygen species (ROS) by the neuropeptide orexin‐A could prevent SAE‐induced oxidative stress and inflammation. Therefore, the aim of this study was to investigate the effects of orexin‐A on oxidative stress and inflammation in SAE in mice.Methods: Adult male mice were treated with orexin‐A (250 μg/kg, intranasal administration) to establish a cecal ligation perforation (CLP) model. We performed behavioral tests, observed neuronal damage in the hippocampal region, measured the levels of ROS, NOX2, and observed the structure of mitochondria by transmission electron microscopy. We then examined the inflammatory factors TNF‐α and IL‐1β, the activation of microglia and astrocytes, the expression of ERK/NF‐κB, C3, and S100A10, and the presence of A1 type astrocytes and A2 type astrocytes.Results: Orexin‐A treatment improved cognitive performance in CLP‐induced SAE mice, attenuated neuronal apoptosis in the hippocampal region, ameliorated ROS levels and the extent of mitochondrial damage, and reduced protein expression of NOX2 in hippocampal tissue. In addition, orexin‐A treatment significantly reduced microglia and astrocyte activation, inhibited the levels of P‐ERK and NF‐κB, and reduced the release of IL‐1β and TNF‐α, which were significantly increased after CLP. Finally, Orexin‐A treatment significantly decreased the number of C3/glial fibrillary acidic protein (GFAP)‐positive cells and increased the number of S100A10/GFAP‐positive cells.Conclusion: Our data suggest that orexin‐A reduces ROS expression by inhibiting CLP‐induced NOX2 production, thereby attenuating mitochondrial damage and neuronal apoptosis. Its inhibition of microglial and A1‐type astrocyte activation and inflammation was associated with the ERK/NF‐κB pathway. These suggest that orexin‐A may reduce cognitive impairment in SAE by reducing oxidative stress‐induced inflammation.

17 May 2024 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
JGJing Guo
Jing Guo
ZKZhuo Kong
Zhuo Kong
SYSha Yang
Sha Yang
JDJingjing Da
Jingjing Da
LCLiangzhao Chu
Liangzhao Chu
JZJiqin Zhang
Jiqin Zhang
Background: Sepsis-associated encephalopathy (SAE) causes acute and long-term cognitive deficits. However, information on the prevention and treatment of cognitive dysfunction after sepsis is limited. The neuropeptide orexin-A (OXA) has been shown to play a protective role against neurological diseases by modulating the inflammatory response through the activation of OXR1 and OXR2 receptors. However, the role of OXA in mediating the neuroprotective effects of SAE has not yet been reported. Methods: A mouse model of SAE was induced using cecal ligation perforation (CLP) and treated via intranasal administration of exogenous OXA after surgery. Mouse survival, in addition to cognitive and anxiety behaviors, were assessed. Changes in neurons, cerebral edema, blood-brain barrier (BBB) permeability, and brain ultrastructure were monitored. Levels of pro-inflammatory factors (IL-1β, TNF-α) and microglial activation were also measured. The underlying molecular mechanisms were investigated by proteomics analysis and western blotting. Results: Intranasal OXA treatment reduced mortality, ameliorated cognitive and emotional deficits, and attenuated cerebral edema, BBB disruption, and ultrastructural brain damage in mice. In addition, OXA significantly reduced the expression of the pro-inflammatory factors IL-1β and TNF-α, and inhibited microglial activation. In addition, OXA downregulated the expression of the Rras and RAS proteins, and reduced the phosphorylation of P-38 and JNK, thus inhibiting activation of the MAPK pathway. JNJ-10,397,049 (an OXR2 blocker) reversed the effect of OXA, whereas SB-334,867 (an OXR1 blocker) did not. Conclusion: This study demonstrated that the intranasal administration of moderate amounts of OXA protects the BBB and inhibits the activation of the OXR2/RAS/MAPK pathway to attenuate the outcome of SAE, suggesting that OXA may be a promising therapeutic approach for the management of SAE.

24 January 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YZYu Zeng
Yu Zeng
JLJian Liu
Jian Liu
ZKZhuo Kong
Zhuo Kong
GHGuoqiang Han
Guoqiang Han
YXYunbiao Xiong
Yunbiao Xiong
YTYing Tan
Ying Tan

5 October 2025 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
SYSha Yang
Sha Yang
MDMei Deng
Mei Deng
XRXiangqian Ren
Xiangqian Ren
FWFang Wang
Fang Wang
ZKZhuo Kong
Zhuo Kong
YTYing Tan
Ying Tan
Background Stroke remains a significant global health challenge, especially in low- and middle-income countries, despite advances in treatment and prevention. Understanding stroke trends is crucial for guiding prevention and healthcare strategies. Methods We analysed global data from the Global Burden of Disease Study 2021 on stroke incidence, prevalence, disability-adjusted life years and mortality from 1990 to 2021. The study focused on the major subtypes of stroke—ischaemic stroke (IS), intracerebral haemorrhage and subarachnoid haemorrhage—examining the effects of age, sex and sociodemographic index (SDI) on stroke outcomes. Decomposition analysis assessed the contributions of population growth, ageing and other factors to stroke burden. The Nordpred Prediction Model was used to forecast stroke trends from 2022 to 2046. Results From 1990 to 2021, global stroke incidence and deaths increased by 70.20% and 32.17%, respectively, driven by population ageing (45.3%) and growth (29.1%). However, age-standardised incidence and mortality rates declined by 21.78% and 39.10%, reflecting improvements in healthcare and risk factor control. IS saw the largest increase in crude incidence (87.97%), with regional disparities, especially in low-SDI countries. By 2046, global stroke incidence and mortality are projected to rise by 20.3% and 35.7%, primarily in low- and middle-SDI countries. Conclusions The global stroke burden is rising, particularly in low-SDI regions, due to ageing and population growth. Declines in age-standardised rates emphasise the importance of healthcare improvements. Region-specific strategies are needed to address the rising burden and reduce disparities in stroke outcomes.

20 July 2023 in Heliyon
Verified
Journal Article
Open access
PZPeng Zhang
Peng Zhang
FCFang Cao
Fang Cao
JZJiqin Zhang
Jiqin Zhang
YTYing Tan
Ying Tan
SYShengtao Yao
Shengtao Yao
The past decades have witnessed great progress in nanoparticle‐based cancer‐targeting drug delivery systems, but their therapeutic potentials is yet to be fully exploited. In this research, temozolomide (TMZ) and chloroquine (CQ) were loaded into the mesoporous silica nanoparticles (MSNs), the surface was coated with polydopamine (PDA), and the complex was coupled with arginine-glycine-aspartic (RGD) to successfully prepare TMZ/CQ@MSN-RGD. RGD-MSNs accumulated more in the cell and tumor models than in unmodified MSNs in the in vitro and in vivo experiments and can directly induce apoptosis and autophagy in tumor cells. In addition, TMZ/CQ@MSN-RGD therapy enhanced the apoptosis effect of the RGD-MSNs in glioma. Therefore, the combination of autophagy inhibitor with chemotherapy drugs in nanocarriers may promote therapeutic efficacy in treating glioma.